Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus, a drug delivery company committed to the creation of improved pharmaceutical products that are based on its proprietary drug delivery technologies, has entered into a pharmaceutical manufacturing and development agreement with US-based The Medicines Company.
Subscribe to our email newsletter
As per the terms of the agreement, OctoPlus is expected to perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).
MDCO-216 is a naturally occurring variant of a protein found in human high-density lipoprotein (HDL). Based upon multiple non-clinical studies and a Phase 1/2 clinical trial of MDCO-216 conducted prior to the exclusive license obtained by The Medicines Company in December 2009, MDCO-216 is believed to have the potential to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS.
OctoPlus is a European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.